Multifunctional Mesoporous Silica-Coated Graphene Nanosheet Used for Chemo-Photothermal Synergistic Targeted Therapy of Glioma

• Published in: Journal of the American Chemical Society Vol. 135; no. 12; pp. 4799 - 4804
• Main Authors: Wang, Yi, Wang, Kaiyuan, Zhao, Jianfeng, Liu, Xingang, Bu, Juan, Yan, Xueying, Huang, Rongqin
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 27-03-2013
• Subjects: Antibiotics, Antineoplastic - administration & dosage; Antibiotics, Antineoplastic - pharmacology; Brain - drug effects; Brain - pathology; Brain Neoplasms - drug therapy; Brain Neoplasms - pathology; Brain Neoplasms - therapy; Cell Line, Tumor; Delayed-Action Preparations - chemistry; Doxorubicin - administration & dosage; Doxorubicin - pharmacology; Drug Delivery Systems - methods; Glioma - drug therapy; Glioma - pathology; Glioma - therapy; Graphite - chemistry; Humans; Hyperthermia, Induced; Nanostructures - chemistry; Photochemical Processes; Photochemotherapy; Protons; Silicon Dioxide - chemistry; Temperature
• ISSN: 0002-7863; 1520-5126
• DOI: 10.1021/ja312221g

Current therapy of malignant glioma in clinic is unsatisfactory with poor patient compliance due to low therapeutic efficiency and strong systemic side effects. Herein, we combined chemo-photothermal targeted therapy of glioma within one novel multifunctional drug delivery system. A targeting peptide (IP)-modified mesoporous silica-coated graphene nanosheet (GSPI) was successfully synthesized and characterized, and first introduced to the drug delivery field. A doxorubicin (DOX)-loaded GSPI-based system (GSPID) showed heat-stimulative, pH-responsive, and sustained release properties. Cytotoxicity experiments demonstrated that combined therapy mediated the highest rate of death of glioma cells compared to that of single chemotherapy or photothermal therapy. Furthermore, the IP modification could significantly enhance the accumulation of GSPID within glioma cells. These findings provided an excellent drug delivery system for combined therapy of glioma due to the advanced chemo-photothermal synergistic targeted therapy and good drug release properties of GSPID, which could effectively avoid frequent and invasive dosing and improve patient compliance.